Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BeiGene, Ltd. (ONC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ONC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $381.09
1 Year Target Price $381.09
| 15 | Strong Buy |
| 8 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.89% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 36.69B USD | Price to earnings Ratio - | 1Y Target Price 381.09 |
Price to earnings Ratio - | 1Y Target Price 381.09 | ||
Volume (30-day avg) 24 | Beta 0.31 | 52 Weeks Range 170.99 - 355.30 | Updated Date 10/17/2025 |
52 Weeks Range 170.99 - 355.30 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.89% | Operating Margin (TTM) 6.68% |
Management Effectiveness
Return on Assets (TTM) -1.06% | Return on Equity (TTM) -4.98% |
Valuation
Trailing PE - | Forward PE 47.85 | Enterprise Value 38727210732 | Price to Sales(TTM) 8.04 |
Enterprise Value 38727210732 | Price to Sales(TTM) 8.04 | ||
Enterprise Value to Revenue 8.49 | Enterprise Value to EBITDA 433.9 | Shares Outstanding 100988458 | Shares Floating 873357144 |
Shares Outstanding 100988458 | Shares Floating 873357144 | ||
Percent Insiders 17.29 | Percent Institutions 32.52 |
Upturn AI SWOT
BeiGene, Ltd.
Company Overview
History and Background
BeiGene, Ltd. was founded in 2010 by Xiaodong Wang and Peter Fang. It is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company has evolved from a China-focused operation to a global player with operations in multiple countries.
Core Business Areas
- Research and Development: BeiGene focuses on discovering and developing innovative oncology medicines. Their research spans early discovery through late-stage clinical development.
- Manufacturing: BeiGene has established manufacturing capabilities, including both small molecule and biologics production.
- Commercialization: BeiGene commercializes its own developed products and in-licensed products in various markets.
Leadership and Structure
BeiGene is led by a team of experienced executives in the pharmaceutical industry. Key leaders include the CEO, Chief Medical Officer, and heads of various departments like R&D, manufacturing, and commercial operations. The company operates with a global structure.
Top Products and Market Share
Key Offerings
- Brukinsa (zanubrutinib): A BTK inhibitor approved for various hematological malignancies. Brukinsa has gained market share rapidly. Competitors include Imbruvica (ibrutinib) by AbbVie and Janssen and Calquence (acalabrutinib) by AstraZeneca. Revenue contribution significant but no readily available exact market share due to multiple indications.
- Tislelizumab: An anti-PD-1 antibody approved in several countries. It is in late stage clinical trials. Competitors are Keytruda (Merck) and Opdivo (Bristol-Myers Squibb).
Market Dynamics
Industry Overview
The oncology therapeutics market is large and growing, driven by an aging population, increased incidence of cancer, and advancements in treatment options like targeted therapies and immunotherapies.
Positioning
BeiGene is positioned as a global oncology company focused on innovation. Its competitive advantages include a strong R&D pipeline, global manufacturing capabilities, and a growing commercial presence. Its focus on affordability also gives it an edge in certain markets.
Total Addressable Market (TAM)
The global oncology market is estimated to be hundreds of billions of dollars. BeiGene aims to capture a significant share of this TAM through its innovative pipeline and global expansion.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Global manufacturing capabilities
- Innovative oncology focus
- Experienced management team
- Focus on Affordability
Weaknesses
- Relatively new commercial presence compared to established players
- Dependence on pipeline success
- High R&D spending
Opportunities
- Expanding into new markets
- Developing new therapies for unmet medical needs
- Forming strategic partnerships
- Expanding access to innovative medicines globally
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- AZN
- MRK
- BMY
Competitive Landscape
BeiGene faces intense competition from established pharmaceutical companies. Its advantages include innovative products and a focus on affordability. Disadvantages include a smaller commercial presence and dependence on pipeline success.
Growth Trajectory and Initiatives
Historical Growth: BeiGene has experienced rapid revenue growth in recent years, driven by product sales and market expansion.
Future Projections: Analysts project continued revenue growth for BeiGene, driven by increased adoption of Brukinsa and potential approval and launch of other pipeline products.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, advancing clinical trials, and expanding commercial operations globally.
Summary
BeiGene is a growing global oncology company with innovative products and a strong pipeline. The company faces competition from established players, and its success depends on the continued development and commercialization of its pipeline. Investment in R&D continues, but will need to manage operating costs to get to a point of breaking even. Current market share is low, but growth opportunities are there if trials continue to perform.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications.
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source and specific indication.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeiGene, Ltd.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-02-03 | Co-Founder, Executive Chairman & CEO Mr. John V. Oyler | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11000 | Website https://beonemedicines.com |
Full time employees 11000 | Website https://beonemedicines.com | ||
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.